I-MED Pharma
- Company typePrivate
- Founded1989
- HeadquartersSaint Laurent, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
I-MED Pharma firmographics
Firmographics- Name
- I-MED Pharma
- Website
- https://imedpharma.com
- Company type
- Private
- Founded year
- 1989
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
I-MED Pharma industry classification
Industry- Product category
- Ophthalmic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
Keywords
Where I-MED Pharma is headquartered
LocationHeadquarters
- HQ city
- Saint Laurent
- HQ country
- Canada
- HQ region
- North America
Markets served
I-MED Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D
I-MED Pharma product offering
Product offeringCore offering
I-MED Pharma is a Canadian pharmaceutical company based in the Montreal area (Dollard-des-Ormeaux/Saint-Laurent) that develops, manufactures, and distributes therapeutic products. Operating since 1989 with 11-50 employees, the company focuses on pharmaceutical formulations for medical use, with branding consistent with ophthalmic and specialty eye-care therapeutics.
Differentiator
Problem solved
Functional benefit
Products and services
- I-MED Pharmaceutical Product Line
Companies that use I-MED Pharma
Customer profileIdeal customer profiles1 record
I-MED Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
I-MED Pharma partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights2 records
I-MED Pharma competitors and assessment
Company assessmentBroad incumbents
- Alcon: World's largest dedicated eye-care company with a full portfolio of ophthalmic pharmaceuticals, surgical, and vision-care products. Comparable to I-MED Pharma along the branded ophthalmic pharma axis; relevant as a benchmark for scale, channel access, and product-range strategy.
- Allergan (AbbVie): Founded as a specialty pharma anchored by ophthalmology brands (e.g., Refresh, Lumigan, Restasis), now part of AbbVie. Comparable to I-MED Pharma as a branded ophthalmic pharma franchise and the historical benchmark for a privately-innovative ophthalmic pharma becoming a global asset.
- Johnson & Johnson Vision: Eyecare division of J&J covering ophthalmic pharmaceutical, surgical, and contact lens products. Comparable to I-MED Pharma in the branded ophthalmic pharma product category; serves as a large-cap reference point.
- Sun Pharmaceutical Industries: India-headquartered global pharma with a significant specialty and ophthalmic generics portfolio. Comparable to I-MED Pharma along the prescription ophthalmic pharmaceutical axis, though at much larger scale and more generic-driven.
- Bausch + Lomb (Bausch Health): Global ophthalmology-focused pharmaceutical and medical device company selling branded Rx eye drops, OTC eye-care, and surgical products. Comparable to I-MED Pharma as a branded ophthalmic pharmaceutical manufacturer, although much larger and broader in product range and geography.
Emerging players
- Akorn / Eyenovia: Smaller specialized ophthalmic pharma players commercializing branded Rx eye drops. Comparable to I-MED Pharma as small-cap, specialty-ophthalmic-pharma manufacturers competing for shelf space in the same prescriber base.
- Aerie Pharmaceuticals: Specialty pharma that developed and commercialized branded glaucoma ophthalmic products (Rhopressa, Rocklatan) before being acquired. Relevant comparable to I-MED Pharma for branded ophthalmic pharma build-and-exit trajectory.
- NovaBay Pharmaceuticals: Small U.S. specialty pharma commercializing prescription ophthalmic products (e.g., Aganocide, i-Lid). Comparable to I-MED Pharma as a small, focused branded ophthalmic pharma company in commercial or near-commercial stages.
Direct peers
- Santen Pharmaceutical: Japan-headquartered specialty ophthalmology pharmaceutical company with a focused portfolio of Rx eye drops for glaucoma, dry eye, and inflammation. Closest direct peer to I-MED Pharma: same business model (branded ophthalmic pharma manufacturer), comparable size footprint, and emphasis on specialty eyecare categories.
- Théa Pharmaceuticals: Independent, family-owned European ophthalmic pharmaceutical company developing and marketing branded eye drops and ocular therapeutics. Closely comparable to I-MED Pharma in size, private/family ownership, and specialty-ophthalmic-pharma focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
I-MED Pharma social profiles
Digital presenceI-MED Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
I-MED Pharma leadership team
Management profileNumber of profiles
Profiles3 records
I-MED Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
I-MED Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about I-MED Pharma
What does I-MED Pharma do?
I-MED Pharma is a Canadian pharmaceutical company based in the Montreal area (Dollard-des-Ormeaux/Saint-Laurent) that develops, manufactures, and distributes therapeutic products. Operating since 1989 with 11-50 employees, the company focuses on pharmaceutical formulations for medical use, with branding consistent with ophthalmic and specialty eye-care therapeutics.
When was I-MED Pharma founded?
I-MED Pharma was founded in 1989. It employs 11 to 50 people.
Where is I-MED Pharma based?
I-MED Pharma is headquartered in Saint Laurent, Canada, in the North America region.
Who are I-MED Pharma's main competitors?
Broad incumbents on record are Alcon, Allergan (AbbVie), Johnson & Johnson Vision, Sun Pharmaceutical Industries and Bausch + Lomb (Bausch Health). Emerging players are Akorn / Eyenovia, Aerie Pharmaceuticals and NovaBay Pharmaceuticals. Direct peers are Santen Pharmaceutical and Théa Pharmaceuticals.
Does I-MED Pharma have an API?
No public API is recorded for I-MED Pharma.
What industry is I-MED Pharma in?
I-MED Pharma's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.